Bayer and MOMA Therapeutics sign pact to develop oncology program

Bayer and MOMA Therapeutics, Inc., a biopharmaceutical company in the clinical stage that focuses on discovering and creating precise therapeutics, have declared a collaboration. This partnership involves an option and exclusive license agreement to work on and market a small molecule oncology program that leverages MOMA's unique KNOMATIC platform. Bayer will be in charge of handling additional preclinical, development, and commercial tasks as per the agreement.

“We are excited to partner with MOMA Therapeutics to explore the untapped potential of highly dynamic proteins in oncology,” said Juergen Eckhardt, M.D., head of business development and licensing at Bayer’s Pharmaceuticals Division. “This collaboration reinforces Bayer’s commitment to precision medicine while enhancing our ability to address significant unmet medical needs in cancer treatment. By leveraging MOMA’s cutting-edge technologies and our expertise, we aim to accelerate the development of innovative therapies that can make a meaningful difference in patients’ lives.”

In the agreement, the leading pharmaceutical firm will receive both the program and the results produced through MOMA's KNOMATIC platform. This system combines in-depth structural knowledge with cutting-edge hit identification techniques and computational lead optimization to speed up the development of drugs that efficiently target highly flexible proteins. Dynamic proteins are a new type of therapeutic targets that have the potential to play important roles in the advancement of diseases. Developing innovative cancer therapies can largely benefit from targeting these proteins through a small molecule approach.